Literature DB >> 2971612

Abnormal T-cell activation in chronic hepatitis B viral infection: a consequence of monocyte dysfunction?

K T Nouri-Aria1, S Magrin, G J Alexander, M G Anderson, R Williams, A L Eddleston.   

Abstract

The process of T-cell activation in chronic hepatitis B virus (HBV) carriers has been investigated by measurement of membrane expression of lymphocyte-activation markers in response to a variety of mitogenic stimuli in order to delineate further the abnormality of T-cell-mediated immunity present in such patients. A substantial proportion of unstimulated T cells from the peripheral blood of patients but not controls expressed HLA-DR; in contrast the IL-2 and transferrin receptors were rarely expressed spontaneously in either group and there was no difference in spontaneous lymphocyte transformation. After stimulation with monocyte-dependent T-cell mitogens, phytohaemagglutinin (PHA) or anti-T3, patients had significantly reduced expression of the IL-2 and transferrin receptors and of HLA-DR in association with impaired lymphocyte transformations compared to controls. In contrast, lymphocyte activation was normal in response to the monocyte-independent T-cell mitogen phorbol-myristate-acetate (PMA). These data confirm that the process of T-cell activation is abnormal in chronic HBV carriers but suggest that the T cell is intrinsically normal. In allogeneic co-cultures, monocytes from patients inhibited the transformation of normal and patients' lymphocytes in response to PHA, suggesting that defects of T-cell-mediated immunity in chronic HBV carriers may be a consequence of monocyte dysfunction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971612      PMCID: PMC1384999     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Thymus-dependent lymphocyte function in patients with hepatitis-associated antigen.

Authors:  V Giustino; F J Dudley; S Sherlock
Journal:  Lancet       Date:  1972-10-21       Impact factor: 79.321

Review 2.  Australia antigen as a hepatitis virus. Variation in host response.

Authors:  B S Blumberg; A I Sutnick; W T London
Journal:  Am J Med       Date:  1970-01       Impact factor: 4.965

3.  Aquisition of hepatitis-associated antigen. Clinical features in young adults.

Authors:  L F Barker; R Murray
Journal:  JAMA       Date:  1971-06-21       Impact factor: 56.272

4.  The glomerular permeability determined by dextran clearance using Sephadex gel filtration.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1968       Impact factor: 1.713

5.  Interferon production by peripheral lymphocytes in HBsAg-positive liver diseases.

Authors:  Y Kato; H Nakagawa; K Kobayashi; N Hattori; K Hatano
Journal:  Hepatology       Date:  1982 Nov-Dec       Impact factor: 17.425

6.  Cell-mediated immunity in HBeAg-positive homosexuals with chronic liver disease.

Authors:  L Viola; I G Barrison; F Paradinas; J C Coleman; I M Murray-Lyon
Journal:  Br J Vener Dis       Date:  1982-02

7.  Exposure to hepatitis B virus and development of the chronic HBAg carrier state in children.

Authors:  R J Gerety; J H Hoofnagle; J A Markenson; L F Barker
Journal:  J Pediatr       Date:  1974-05       Impact factor: 4.406

8.  Incidence of infective hepatitis followed by Down's syndrome nine months later.

Authors:  A Stoller; R D Collmann
Journal:  Lancet       Date:  1965-12-11       Impact factor: 79.321

9.  Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis.

Authors:  E Sagnelli; G Manzillo; G Maio; G Pasquale; F M Felaco; P Filippini; C M Izzo; F Piccinino
Journal:  Lancet       Date:  1980-08-23       Impact factor: 79.321

10.  Functional properties of lymphocyte subpopulations in hepatitis B virus infection. I. Suppressor cell control of T lymphocyte responsiveness.

Authors:  F V Chisari; K L Castle; C Xavier; D S Anderson
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

View more
  8 in total

Review 1.  Hepatology.

Authors:  P M Harrison; J Y Lau; R Williams
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

Review 2.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

3.  Effects of mitogens and lymphokines on the regulation of the immune response to HBs antigen in vitro.

Authors:  I Knöller; U J Hoffmann; H H Werchau; W König
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

4.  Low frequency, weak MCP-1 secretion and exhausted immune status of peripheral monocytes were associated with progression of severe enterovirus A71-infected hand, foot and mouth disease.

Authors:  X Pei; X Fan; H Zhang; H Duan; C Xu; B Xie; L Wang; X Li; Y Peng; T Shen
Journal:  Clin Exp Immunol       Date:  2019-02-17       Impact factor: 4.330

5.  Hepatic expression of tumour necrosis factor-alpha in chronic hepatitis B virus infection.

Authors:  M J Hussain; J Y Lau; R Williams; D Vergani
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

6.  Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors.

Authors:  Y Ilan; A Nagler; D Shouval; A Ackerstein; R Or; J Kapelushnik; R Adler; S Slavin
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

7.  Effects of alpha-interferon on gamma-interferon production of peripheral blood mononuclear cells in hepatitis B virus carriers.

Authors:  K Katayama; N Hayashi; T Takehara; T Towata; A Kasahara; H Fusamoto; T Kamada
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

8.  T lymphocyte activation is associated with viral replication in chronic hepatitis B virus infection of childhood.

Authors:  A Vegnente; S Guida; A Lobo-Yeo; L Alviggi; H Daniels; P Toscano; V Nuzzo; G Mieli-Vergani; D Vergani
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.